NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(...(our unique low frequency ultrasound plat...),Health

Date:4/21/2009

our unique low frequency ultrasound platform, has been shown in a number of independent studies to have powerful tissue regenerative properties. NanoVibronix has created a platform that allows physicians to easily apply therapeutic ultrasound to assist in wound healing without interfering with any of the other modalities that are being utilized. Our simple-to-use, portable patch-based device can treat wounds in the hospital or at home, allowing patients to continue with their daily activities."

About the Company

NanoVibronix, located in Nesher Israel, develops medical devices that implement its proprietary therapeutic ultrasound technology. The innovative portable PainShield device for treatment of pain gained FDA clearance in October 2008. The Company is planning to launch the product in the USA during the second half of 2009. The company has also developed a unique line of catheter-based disposable ultrasound devices designed to treat catheter associated injury including pain, discomfort and biofilm formation. The first two products in this family are the UroShield(TM) for indwelling urinary catheters and the NG-Shield(TM) for indwelling Nasogastric tubes.

   http://www.nanovibronix.com

    For more information, please contact:

    Amir Rippel, VP Marketing
    NanoVibronix Ltd.
    Tel: +972-4-820-0581
    Fax: +972-4-820-2794
    info@nanovibronix.com

'/>"/>

SOURCE NanoVibronix Ltd. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2
Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units